

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

## Can-Fite BioPharma Ltd. (NYSE/CANF)

January 31, 2022

### BUY-Rated: Nash Trial Begins – First Patient Enrolled

Jason H. Kolbert

Senior Healthcare Analyst

[jkolbert@dawsonjames.com](mailto:jkolbert@dawsonjames.com)

*Can-Fite BioPharma announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH.*

### Investment Highlights

**Namodenoson in NASH:** The first patient is now enrolled in the Phase 2b study.

- The study plans to enroll N=140 patients with biopsy-confirmed NASH with a primary endpoint to evaluate the efficacy of Namodenoson as compared to placebo, as determined by a histological endpoint. Patients will be randomly assigned in a 2:1 ratio to oral doses of Namodenoson 25 mg or placebo every 12 hours for 36 weeks.

**Liver Cancer:** Patient Enrollment Expected to Commence in the Phase 3 Study H122

- In December, Can-Fite announced that a prior Phase II liver cancer study patient who continues to be treated with Namodenoson has survived five years and cleared all cancer lesions. We see this as a very positive sign as we expect the company to commence enrollment in Q1 of 2022.
- Approximately 450 patients diagnosed with hepatocellular carcinoma (HCC) and underlying Child Pugh B7 (CPB7) who have not responded to other approved therapies will be enrolled through clinical sites worldwide. Patients will be randomized to oral treatment with either 25 mg Namodenoson or matching placebo given twice daily. The primary efficacy endpoint of the trial is overall survival.
- An interim analysis is set once 50% of patients are enrolled.


**COMFORT-Plaque Psoriasis:** Topline Phase 3 Psoriasis Data Expected Q122

- Comfort Phase 3 study of Piclidenoson enrolled and treated approximately 400 patients with moderate to severe plaque psoriasis. In Q1 Can-Fite expects to announce results from the first 16 weeks of treatment, with the primary endpoint of the study being a statistically significant improvement in achieving a PASI score of 75 in Piclidenoson treated patients vs. placebo.
- Later in 2022 the company expects to announce the study's secondary endpoint at 32 weeks of treatment which is non-inferiority of Piclidenoson vs. Otezla. The study has four treatment arms: Piclidenoson 2 mg, Piclidenoson 3 mg, Otezla, and placebo.

**Valuation.** We evaluate Piclidenoson in Psoriasis, Namodenoson in HCC, and NAFLD. We apply a probability of success in these patient-based models. These metrics then flow into our valuation models. For Can-Fite, we use a 30% discount rate and apply a therapeutic probability of success rate (in that model). Our risk rate in our financial models is 30% as Can-Fite is not yet profitable, and most of the products are still dependent on the outcome of the clinical trials. Our valuation conclusion is an equally-weighted average of our FCFF, EPS, and sum-of-the-parts analysis. We use a projected fully diluted end-year share count and assume multiple raises. The conclusion of this method is a \$5.00 price target.

**Risks to our thesis include the following:** (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.


Current Price \$1.15  
Price Target \$5.00



Source: Can-Fite

#### Stock Data

52-Week Range	\$0.94	-	\$4.39
Shares Outstanding (mil.)	27.2		
Market Capitalization (mil.)	\$31.3		
Enterprise Value (mil.)	\$11.2		
Debt to Capital	0.0%		
Book Value/Share	\$4.52		
Price/Book	4.5		
Average Three Months Trading Volume (M)	0.3		
Insider Ownership	0.1%		
Institutional Ownership	6.0%		
Short interest (mil.)	4.4%		
Dividend / Yield	\$0.00/0.0%		



**Product Modeling Assumptions**

1. We assume the program in RA does not continue but Psoriasis does to a second pivotal trial. If we assume a similar size, cost, and time for the studies, it suggests we could see U.S. top line data in a year from the current trial.
2. We assume Can-Fite may partner Piclidenoson (and Namodenoson). For the purpose of our model, we assume a sliding scale royalty at a base of 25% but rising to 30% based on sales levels. In accordance with this assumption, we only moderately increase G&A expenses as the Company is not likely to build a salesforce in this scenario.
3. We assume pricing of \$5,000 in the U.S. and \$3,000 in Europe with 2% year on year increases for Piclidenoson in Psoriasis, and the target population is assumed to be high A<sub>3</sub>AR expressers.
4. A probability success factor of 50% to our models for Psoriasis.
5. We assume Namodenoson is approved and launches (U.S. and Europe), for late-stage liver cancer in 2024.
6. We assume Namodenoson pricing of \$50,000 in the U.S. and \$35,000 in Europe with a 2% y/y increase.
7. A probability success factor of 50% is applied to our HCC model-based, which is based on Phase 2 data.
8. A probability success factor of 10% to our U.S. and EU models for NAFLD/NASH as the current Phase 2 study is exploratory, and the clinical development pathway for this indication is long and expensive and may require a partner to pay development costs. As such, we believe it's prudent to heavily discount the indication.
9. We do not include CF 602 for the ED indication in our model as the product is still in early stages of testing. We assume a partner is needed to move the project into the clinic.
10. We do not include any estimates for COVID.

**Exhibit 1. Product Market Models**

Piclidenoson - CF101 (US)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Psoriasis incidence	7,178,760	7,322,335	7,468,782	7,618,158	7,770,521	7,925,931	8,084,450	8,246,139	8,411,061	8,579,283	8,750,868	8,925,886	9,104,403
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Plaque psoriasis (80%)	5,743,008	5,857,868	5,975,026	6,094,526	6,216,417	6,340,745	6,467,560	6,596,911	6,728,849	6,863,426	7,000,695	7,140,709	7,283,523
Moderate to severe plaque psoriasis (17%)	976,311	995,838	1,015,754	1,036,069	1,056,791	1,077,927	1,099,485	1,121,475	1,143,904	1,166,782	1,190,118	1,213,920	1,238,199
Patients seeking treatment (84%)	820,102	836,504	853,234	870,298	887,704	905,458	923,568	942,039	960,880	980,007	999,699	1,019,893	1,040,687
Market Penetration					0.0%	3.0%	6.0%	7.0%	8.0%	9.0%	10.0%	10.0%	11.0%
Patients receiving CF101					27,707	56,522	67,262	78,408	89,973	101,969	114,410	127,311	140,662
Annual cost of treatment					\$ 5,000	\$ 5,100	\$ 5,202	\$ 5,306	\$ 5,412	\$ 5,520	\$ 5,631	\$ 5,743	\$ 5,857
Increase in Price					2%	2%	2%	2%	2%	2%	2%	2%	2%
Revenue ('000)					\$ -	\$ 141,306	\$ 294,029	\$ 356,893	\$ 424,356	\$ 496,687	\$ 574,170	\$ 657,103	\$ 743,811
Probability of Success					65%	65%	65%	65%	65%	65%	65%	65%	65%
<b>Total Revenue ('000)</b>					\$ -	\$ 91,849	\$ 191,119	\$ 231,980	\$ 275,831	\$ 322,846	\$ 373,211	\$ 427,117	\$ 484,596

Source: Company reports and Dawson James Securities

Piclidenoson - CF101 (EU)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Psoriasis incidence	11,548,440	11,779,409	12,014,997	12,255,297	12,500,403	12,750,411	13,005,419	13,265,528	13,530,838	13,801,455	14,077,484	14,359,034	14,646,214
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Plaque psoriasis (80%)	9,238,752	9,423,527	9,611,998	9,804,238	10,000,322	10,200,329	10,404,335	10,612,422	10,824,670	11,041,164	11,261,987	11,487,227	11,716,971
Moderate to severe plaque psoriasis (17%)	1,570,588	1,602,000	1,634,040	1,666,720	1,700,055	1,734,056	1,768,737	1,804,112	1,840,194	1,876,998	1,914,538	1,952,289	1,991,885
Patients seeking treatment (84%)	1,319,294	1,345,680	1,372,593	1,400,045	1,428,046	1,456,607	1,485,739	1,515,454	1,545,763	1,576,678	1,608,212	1,640,376	1,673,184
Market Penetration					0.0%	2.0%	5.0%	10.0%	11.0%	12.0%	13.0%	14.0%	14.0%
Patients receiving CF101						29,715	136,991	154,576	173,435	192,985	213,249	234,246	255,975
Price of treatment					\$ 3,000	\$ 3,060	\$ 3,121	\$ 3,184	\$ 3,247	\$ 3,312	\$ 3,378	\$ 3,446	\$ 3,515
Increase in Price					2%	2%	2%	2%	2%	2%	2%	2%	2%
Revenue ('000)					\$ -	\$ 90,927	\$ 425,703	\$ 492,113	\$ 563,194	\$ 639,214	\$ 720,459	\$ 807,224	\$ 894,596
Probability of Success					65%	65%	65%	65%	65%	65%	65%	65%	65%
<b>Total Revenue ('000)</b>					\$ -	\$ 59,103	\$ 276,707	\$ 319,873	\$ 366,076	\$ 415,489	\$ 468,298	\$ 524,696	\$ 582,811

Namodenoson - CF102 (US)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Hepatocellular Carcinoma incidence	42,335	43,202	44,066	44,947	45,846	46,763	47,698	48,652	49,625	50,618	51,630	52,663	53,716
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
% of deaths due to Sorafenib in patients with Barcelona Clinic Liver Cancer stage CHCC (84%)	27,107	27,649	28,202	28,766	29,341	29,928	30,527	31,137	31,760	32,395	33,043	33,704	34,378
Market Penetration					0.0%	1.0%	5.0%	6.0%	7.0%	8.0%	9.0%	10.0%	10.0%
Patients receiving CF101						305	1,557	1,908	2,263	2,643	3,033	3,438	3,857
Price of treatment					\$ 50,000	\$ 51,000	\$ 52,020	\$ 53,060	\$ 54,122	\$ 55,204	\$ 56,308	\$ 57,434	\$ 58,583
Increase in Price					2%	2%	2%	2%	2%	2%	2%	2%	2%
Revenue ('000)					\$ -	\$ -	\$ 15,880	\$ 82,608	\$ 103,135	\$ 125,185	\$ 148,848	\$ 174,220	\$ 201,398
Probability of Success					50%	50%	50%	50%	50%	50%	50%	50%	50%
<b>Total Revenue ('000)</b>					\$ -	\$ -	\$ 7,340	\$ 11,995	\$ 57,716	\$ 72,057	\$ 87,463	\$ 103,996	\$ 121,722

Namodenoson - CF102 (EU)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Hepatocellular Carcinoma incidence	54,111	55,193	56,297	57,423	58,572	59,743	60,938	62,157	63,400	64,668	65,961	67,280	68,626
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
% of death occurrence due to Sorafenib in patients with Barcelona Clinic Liver Cancer stage C HCC (64%)	34,631	35,324	36,030	36,751	37,486	38,236	39,000	39,780	40,576	41,387	42,215	43,060	43,921
Market Penetration					0.0%	0.0%	1.0%	5.0%	6.0%	7.0%	8.0%	9.0%	10.0%
Patients receiving CF101						609	3,108	3,804	4,527	5,277	6,055	6,863	7,702
Price of treatment					\$ 35,000	\$ 35,700	\$ 36,414	\$ 37,142	\$ 37,885	\$ 38,643	\$ 39,416	\$ 40,204	\$ 41,008
Increase in Price					2%	2%	2%	2%	2%	2%	2%	2%	2%
Revenue ('000)					\$ -	\$ -	\$ 22,190	\$ 115,432	\$ 144,115	\$ 174,927	\$ 207,993	\$ 243,445	\$ 281,422
Probability of Success					50%	50%	50%	50%	50%	50%	50%	50%	50%
<b>Total Revenue ('000)</b>					\$ -	\$ -	\$ 11,095	\$ 57,716	\$ 72,057	\$ 87,463	\$ 103,996	\$ 121,722	\$ 140,711

Namodenoson - CF102 (US)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
NAFLD/NASH	11,548,440	11,779,409	12,014,997	12,255,297	12,500,403	12,750,411	13,005,419	13,265,528	13,530,838	13,801,455	14,077,484	14,359,034	14,646,214
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Market Penetration					0.0%	0.25%	0.50%	0.75%	1.00%	1.00%	1.00%	1.00%	1.00%
Patients receiving CF101							32,514	66,328	101,481	138,015	140,775	143,590	146,462
Price of treatment							\$ 25,000	\$ 25,500	\$ 26,010	\$ 26,530	\$ 27,061	\$ 27,602	\$ 28,154
Increase in Price							2%	2%	2%	2%	2%	2%	2%
Revenue ('000)							\$ -	\$ 812,839	\$ 1,691,355	\$ 2,639,528	\$ 3,661,554	\$ 4,750,480	\$ 5,903,383
Probability of Success					10%	10%	10%	10%	10%	10%	10%	10%	10%
<b>Total Revenue ('000)</b>					\$ -	\$ -	\$ 81,284	\$ 169,135	\$ 263,953	\$ 366,155	\$ 477,028	\$ 593,338	\$ 720,350

Namodenoson - CF102 (EU-S)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
NAFLD/NASH	11,548,440	11,779,409	12,014,997	12,255,297	12,500,403	12,750,411	13,005,419	13,265,528	13,530,838	13,801,455	14,077,484	14,359,034	14,646,214
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Market Penetration					0.0%	0.25%	0.50%	0.75%	1.00%	1.00%	1.00%	1.00%	1.00%
Patients receiving CF101							33,164	67,854	103,511	140,775	143,590	146,462	149,393
Price of treatment							\$ 20,000	\$ 20,400	\$ 20,808	\$ 21,224	\$ 21,649	\$ 22,082	\$ 22,523
Increase in Price							2%	2%	2%	2%	2%	2%	2%
Revenue ('000)							\$ -	\$ 676,542	\$ 1,407,748	\$ 2,196,932	\$ 3,047,684	\$ 3,970,707	\$ 4,963,803
Probability of Success					10%	10%	10%	10%	10%	10%	10%	10%	10%
<b>Total Revenue ('000)</b>					\$ -	\$ -	\$ -	\$ 67,654	\$ 140,775	\$ 219,693	\$ 304,758	\$ 397,071	\$ 493,880

Source: Dawson James Securities estimates, company reports

**Exhibit 2. Income Statement**

Can-Fite Biopharma.: Income Statement (\$'000)																
.: YE December 31	2019A	2020A	1Q21A	2Q21A	3Q21A	4Q21E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
<b>Revenue:</b>	2,032	763	148	250	252	-	650	-	-	-	-	-	-	-	-	-
Piclidensoson (CF-101), Rheumatoid Arthritis U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidensoson (CF-101), Rheumatoid Arthritis EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidensoson (CF-101), Psoriasis U.S.	-	-	-	-	-	-	-	-	-	91,849	191,119	231,980	275,831	322,846	373,211	427,117
Piclidensoson (CF-101), Psoriasis EU	-	-	-	-	-	-	-	-	-	59,103	276,707	319,873	366,076	415,489	468,298	524,696
Namodenoson HCC U.S.	-	-	-	-	-	-	-	-	-	7,940	41,304	51,567	62,592	74,424	87,110	100,699
Namodenoson HCC EU	-	-	-	-	-	-	-	-	-	11,095	57,716	72,057	87,463	103,996	121,722	140,711
Namodenoson NASH/NAFLD U.S.	-	-	-	-	-	-	-	-	-	81,284	169,135	263,953	366,155	380,948	396,338	412,350
Namodenoson NASH/NAFLD EU	-	-	-	-	-	-	-	-	-	-	67,654	140,775	219,693	304,758	317,071	329,880
<b>Total Product Sales</b>	2,032	763	148	250	252	-	650	-	-	158,892	509,130	603,421	704,499	812,760	928,618	1,052,512
Milestone From Gebro Holdings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidensoson (CF-101), Rheumatoid Arthritis U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidensoson (CF-101), Rheumatoid Arthritis EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidensoson (CF-101), Psoriasis U.S.	-	-	-	-	-	-	-	-	-	22,962	47,780	57,995	68,958	80,712	93,303	106,779
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	39%	17%	18%	19%	19%	20%	20%
Piclidensoson (CF-101), Psoriasis EU	-	-	-	-	-	-	-	-	-	22,962	47,780	57,995	68,958	80,712	93,303	106,779
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	39%	17%	18%	19%	19%	20%	20%
Namodenoson HCC U.S.	-	-	-	-	-	-	-	-	-	1,985	10,326	12,892	15,648	18,606	21,777	25,175
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	25%	25%	25%	25%	25%	25%	25%
Namodenoson HCC EU	-	-	-	-	-	-	-	-	-	2,774	14,429	18,014	23,615	28,079	32,865	37,992
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	25%	25%	25%	27%	27%	27%	27%
Namodenoson NASH/NAFLD U.S.	-	-	-	-	-	-	-	-	-	20,321	42,284	65,988	93,223	96,989	100,908	104,984
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	25%	25%	25%	25%	25%	25%	25%
Namodenoson NASH/NAFLD EU	-	-	-	-	-	-	-	-	-	-	16,914	35,194	54,923	76,190	79,268	82,470
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	25%	25%	25%	25%	25%	25%
<b>Total royalties, collaborative revenue</b>	-	-	-	-	-	-	-	-	-	71,004	179,512	248,078	325,325	381,287	421,423	464,180
<b>Total Revenue</b>	2,032	763	148	250	252	-	650	-	-	71,004	179,512	248,078	325,325	381,287	421,423	464,180
<b>Expenses:</b>																
Partnership Costs including COGS	-	-	-	-	-	-	-	-	-	7,945	25,457	30,171	35,225	40,638	46,431	52,626
Research and Development	10,976	11,951	1,303	2,507	2,940	6,750	6,885	7,023	7,163	7,306	7,453	7,602	7,754	7,909	8,067	
General and Administrative	3,059	2,951	1,016	876	818	2,710	8,000	12,000	12,600	13,230	13,892	14,586	15,315	16,081	16,885	
<b>Total Expenses</b>	14,035	14,902	2,319	3,383	3,758	9,460	14,885	19,023	27,708	45,993	51,515	57,413	63,707	70,421	77,578	
Operating Income (Loss)	(12,003)	(14,139)	(2,171)	(3,133)	(3,506)	(8,810)	(14,885)	(19,023)	43,296	133,519	196,563	267,913	317,580	351,002	386,602	
Finance expenses	693	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finance income	3,109	(304)	293	(86)	103	310	-	-	-	-	-	-	-	-	-	-
<b>Total Other Income</b>	2,416	(304)	293	(86)	103	310	-	-	-	-	-	-	-	-	-	-
<b>Pretax Income</b>	(9,587)	(13,835)	(1,878)	(3,047)	(3,609)	(9,120)	(14,885)	(19,023)	43,296	133,519	196,563	267,913	317,580	351,002	386,602	
Taxes on income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustments arising from translating financial statements of foreign operations	-	(715)	-	-	-	-	-	-	2,165	10,682	23,588	66,978	95,274	112,321	131,445	
Remeasurement loss from defined benefit plans	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Tax Rate</b>	-	-	-	-	-	-	-	-	5%	8%	12%	25%	30%	32%	34%	
<b>GAAP Net Income (Loss)</b>	(9,587)	(14,443)	(1,878)	(3,047)	(3,609)	(9,120)	(14,885)	(19,023)	43,296	133,519	196,563	267,913	317,580	351,002	386,602	
<b>Total comprehensive loss</b>	(9,587)	(15,158)	(1,878)	(3,047)	(3,609)	(9,120)	(14,885)	(19,023)	45,461	122,838	172,976	200,934	222,306	238,682	255,157	
<b>GAAP-EPS</b>	(1.77)	(1.02)	(0.11)	(0.16)	(0.16)	(0.43)	(0.30)	(0.38)	0.86	2.63	3.86	5.24	6.19	6.82	7.48	
GAAP-EPS (Dil)	(1.35)	(0.48)	(0.06)	(0.05)	(0.16)	(0.21)	(0.19)	(0.24)	0.54	1.65	2.41	3.28	3.87	4.26	4.67	
Wgtd Avg ADR Shrs (Bas) - '000s	5,833	17,191	17,191	19,091	22,192	30,000	22,118	50,075	50,276	50,477	50,679	50,882	51,086	51,291	51,496	51,703
Wgtd Avg ADR Shrs (Dil) - '000s	8,910	29,866	29,866	60,000	22,192	60,000	43,014	80,120	80,441	80,763	81,087	81,412	81,738	82,065	82,394	82,724

Source: Dawson James Securities estimates, company reports

**Risk Analysis**

In addition to the typical risks associated with development stage specialty pharmaceutical companies, potential risks specific to Can-Fite are as follows:

**Financial risk.** The Company may need to raise capital in the marketplace, and there can be no assurances that the Company will be able to successfully raise capital and/or do so on favorable terms.

**Clinical and regulatory risk.** Lead products must start and complete clinical trials. Trials may not produce results sufficient for regulatory approval.


**Partnership risk.** Can-Fite may seek partnerships for clinical development support and commercialization. We have no specific knowledge of any discussions with possible partners today, and there can be no assurances that the Company will be able to secure a favorable partnership.

**Commercial risk.** There are no assurances that the Company will be able to secure favorable pricing, commercially launch products, and achieve significant market share to become profitable.

**Legal and intellectual property risk.** The Company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the Company may infringe on third parties' patents.

**Important Disclosures:**

**Price Chart:**



Price target and rating changes over the past three years:

- Initiated – Buy – December 13, 2018 – Price Target \$7
- Update – Buy – March 26, 2019 – Price Target \$6
- Update – Buy – May 21, 2019 – Price Target \$9 (adjusted down after reverse stock split).
- Update – Buy – August 7, 2019 – Price Target \$9
- Update – Buy – September 11, 2019 – Price Target \$9
- Update – Buy – September 18, 2019 – Price Target \$9
- Update – Buy – September 23, 2019 – Price Target \$9
- Update – Buy – October 15, 2019 – Price Target \$9
- Update – Buy – October 31, 2019 – Price Target \$9
- Update – Buy – November 4, 2019 – Price Target \$9
- Update – Buy – December 2, 2019 – Price Target \$9
- Update – Buy – December 11, 2019 – Price Target \$9
- Update – Buy – February 3, 2020 – Price Target \$9
- Update – Buy – February 19, 2020 – Price Target \$9
- Update – Buy – March 5, 2020 – Price Target \$9

Update – Buy – April 13, 2020 – Price Target \$9  
Update – Buy – April 20, 2020 – Price Target \$9  
Update – Buy – May 19, 2020 – Price Target \$9  
Update – Buy – June 1, 2020 – Price Target \$9  
Update – Buy – June 9, 2020 – Price Target \$9  
PT Change – Buy – June 10, 2020 – Price Target lowered from \$9 to \$7.0  
Update – Buy – June 30, 2020 – Price Target \$7  
Update – Buy – July 30, 2020 – Price Target \$7  
Update – Buy – August 31, 2020 – Price Target \$7  
PT Change – Buy – October 6, 2020 – Price Target \$5  
Update – Buy – November 16, 2020 – Price Target \$5  
Update – Buy – December 1, 2020 – Price Target \$5  
Update – Buy – January 25, 2021 – Price Target \$5  
Update – Buy – February 23, 2021 – Price Target \$5  
Update – Buy – March 5, 2021 – Price Target \$5  
Update – Buy – March 29, 2021 – Price Target \$5  
Update – Buy – April 22, 2021 – Price Target \$5  
Update – Buy – April 29, 2021 – Price Target \$5  
Update – Buy – May 27, 2021 – Price Target \$5  
Update – Buy – June 4, 2021 – Price Target \$5  
Update – Buy – July 8, 2021 – Price Target \$5  
Update – Buy – August 27, 2021 – Price Target \$5  
Update – Buy – December 7, 2021 – Price Target \$5  
Update – Buy – December 20, 2021 – Price Target \$5  
Update – Buy – January 5, 2022 – Price Target \$5  
Update – Buy – January 31, 2022 – Price Target \$5

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject Company (s). The Firm has NOT engaged in investment banking relationships with CANF in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company (s). The Firm has NOT received other compensation from the subject Company (s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company (s) in this report and may increase or decrease holdings in the future. As of December 31, 2021, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company (s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

**Information about risks can be found in the "RISK ANALYSIS" sections of this report.**

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Rating Definitions:**

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of... 31-Jan-22

	<b>Company Coverage</b>		<b>Investment Banking</b>	
<b>Ratings Distribution</b>	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	29	73%	6	21%
Market Perform (Neutral)	11	28%	0	0%
Market Underperform (Sell)	0	0%	0	0%
<b>Total</b>	<b>40</b>	<b>100%</b>	<b>6</b>	<b>15%</b>

**Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.